Change in treatment outcome with timea
| 2011–2013 | 2014–2015 | 2016–2017 | 2018–2019 | P Value | Total (n = 378) | |
|---|---|---|---|---|---|---|
| (n = 76) | (n = 118) | (n = 94) | (n = 90) | |||
| Last follow-up imaging lapsed time (months)b | 14.0 [28.8] | 24.0 [24.0] | 14.0 [16.5] | 6.80 [5.00] | <.001 | 13.0 [20.6] |
| Last follow-up clinical time from treatment (months)c | 22.5 [40.5] | 29.0 [29.0] | 17.0 [17.3] | 6.50 [6.00] | <.001 | 13.0 [24.0] |
| Follow-up occlusion rated | ||||||
| Complete occlusion (100%) | 47 (66.2%) | 75 (68.9%) | 69 (77.5%) | 46 (67.7%) | .273 | 237 (70.3%) |
| Incomplete occlusion (<90%) | 15 (21.1%) | 14 (12.8%) | 7 (7.9%) | 12 (17.6%) | 48 (14.2%) | |
| Near-complete occlusion (90%–99%) | 9 (12.7%) | 20 (18.3%) | 13 (14.6%) | 10 (14.7%) | 52 (15.4%) | |
| Retreatmente | 9 (12.2%) | 13 (11.2%) | 5 (5.4%) | 3 (3.5%) | .092 | 30 (8.2%) |
| mRS on last follow-upf | ||||||
| 0–2 | 66 (88.0%) | 96 (84.2%) | 82 (87.2%) | 78 (88.6%) | .793 | 322 (86.8%) |
| 3–6 | 9 (12.0%) | 18 (15.8%) | 12 (12.8%) | 10 (11.4%) | 49 (13.2%) | |
| Follow-up mRSf | ||||||
| Improved | 23 (30.7%) | 28 (24.6%) | 21 (22.3%) | 10 (11.4%) | .034 | 82 (22.1%) |
| No change | 40 (53.3%) | 65 (57.0%) | 58 (61.7%) | 68 (77.2%) | 231 (62.3%) | |
| Worsened | 12 (16.0%) | 21 (18.4%) | 15 (16.0%) | 10 (11.4%) | 58 (15.6%) | |
| Neurologic complications | ||||||
| Thromboembolic | 12 (15.8%) | 19 (16.1%) | 10 (10.6%) | 8 (8.9%) | .342 | 49 (13.0%) |
| Thromboembolic (symptomatic) | 9 (11.8%) | 14 (11.9%) | 3 (3.2%) | 7 (7.8%) | .107 | 33 (8.7%) |
| Hemorrhagic | 5 (6.6%) | 5 (4.2%) | 4 (4.3%) | 3 (3.3%) | .781 | 17 (4.5%) |
| Hemorrhagic (symptomatic) | 3 (3.9%) | 4 (3.4%) | 3 (3.2%) | 3 (3.3%) | .994 | 13 (3.4%) |
| Other procedural related complications | 7 (9.2%) | 9 (7.6%) | 4 (4.3%) | 5 (5.6%) | .57 | 25 (6.6%) |
| Mortalityf | 6 (8.0%) | 9 (7.9%) | 5 (5.3%) | 6 (6.8%) | .881 | 26 (7.0%) |